Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry E Gidal

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
Epilepsia|September 3, 2015
Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteersLindy L Bancke, Heather A Dworak, Keith A Rodvold, et al.
Archives of Neurology|April 12, 2006
Protracted ictal confusion in elderly patientsRaj D Sheth, Joseph F Drazkowski, Joseph I Sirven, et al.
Epilepsia|February 18, 2020
Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteersR Edward Hogan, Barry E Gidal, Barry Koplowitz, et al.
Epilepsy Currents|September 23, 2024
The Tell on TelehealthAnup D Patel, Charuta Joshi, Rohit Das, et al.
Epilepsy Research|May 24, 2017
Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design mattersBarry E Gidal, Rama Maganti, Antonio Laurenza, et al.
Epilepsia|September 29, 2012
Enzyme induction with antiepileptic drugs: cause for concern?Martin J Brodie, Scott Mintzer, Alison M Pack, et al.
Epilepsy Research|June 19, 2017
Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transportersBarry E Gidal, Scott Mintzer, Matthias Schwab, et al.
Neurology|April 17, 2015
Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsyBarry E Gidal, Antonio Laurenza, Ziad Hussein, et al.
Clinical Pharmacokinetics|October 3, 2013
Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: the four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designsFrancisco J Diaz, Michel J Berg, Ron Krebill, et al.
Epilepsy & Behavior : E&B|May 3, 2014
The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studiesBarry E Gidal, Oneeb Majid, Jim Ferry, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Epilepsia|September 3, 2015
Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteersLindy L Bancke, Heather A Dworak, Keith A Rodvold, et al.
Archives of Neurology|April 12, 2006
Protracted ictal confusion in elderly patientsRaj D Sheth, Joseph F Drazkowski, Joseph I Sirven, et al.
Epilepsia|February 18, 2020
Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteersR Edward Hogan, Barry E Gidal, Barry Koplowitz, et al.
Epilepsy Currents|September 23, 2024
The Tell on TelehealthAnup D Patel, Charuta Joshi, Rohit Das, et al.
Epilepsy Research|May 24, 2017
Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design mattersBarry E Gidal, Rama Maganti, Antonio Laurenza, et al.
Epilepsia|September 29, 2012
Enzyme induction with antiepileptic drugs: cause for concern?Martin J Brodie, Scott Mintzer, Alison M Pack, et al.
Epilepsy Research|June 19, 2017
Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transportersBarry E Gidal, Scott Mintzer, Matthias Schwab, et al.
Neurology|April 17, 2015
Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsyBarry E Gidal, Antonio Laurenza, Ziad Hussein, et al.
Clinical Pharmacokinetics|October 3, 2013
Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: the four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designsFrancisco J Diaz, Michel J Berg, Ron Krebill, et al.
Epilepsy & Behavior : E&B|May 3, 2014
The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studiesBarry E Gidal, Oneeb Majid, Jim Ferry, et al.
Pageof 9